Thalassemia Patients and Friends

Discussion Forums => Working Towards a Cure => Topic started by: ironjustice on March 15, 2022, 07:02:59 PM

Title: Pyruvate Kinase Activation
Post by: ironjustice on March 15, 2022, 07:02:59 PM

Would this give credence to the theory of iron, before, the manifestation of Thalassemia?
Since iron inhibits pyruvate kinase?

The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model
https://pubmed.ncbi.nlm.nih.gov/33822774/


Iron-Dependent Oxidative Inactivation with Affinity Cleavage of Pyruvate Kinase.
https://link.springer.com/article/10.1007/s12011-009-8317-x

Title: Re: Pyruvate Kinase Activation
Post by: raziqrazac on March 20, 2022, 07:22:26 PM

This looks interesting. Is this treatment in the market now ?

Title: Re: Pyruvate Kinase Activation
Post by: Andy Battaglia on March 23, 2022, 04:55:57 AM

It was just approved in the US in February, 2022.
http://drugapprovalsint.com/mitapivat/

Quote

On February 17, 2022, the FDA approved mitapivat as the first disease-modifying treatment for hemolytic anemia in adults with pyruvate kinase (PK) deficiency, a rare, inherited disorder leading to lifelong hemolytic anemia.6 Mitapivat has also been investigated in other hereditary red blood cell disorders associated with hemolytic anemia, such as sickle cell disease and alpha- and beta-thalassemia.1